Welcome and introduction

Anja Tuulonen

Randomized controlled trials of clinical effectiveness and outcome measures

David Garway-Heath

Systematic reviews of randomized controlled trials and measures of effect

Richard Wormald

Diagnostic test accuracy study designs and risk of bias

Augusto Azuara-Blanco

Systematic reviews of diagnostic accuracy and measures of accuracy

Gianni Virgili

Systematic reviews of observational studies

Gianni Virgili

Grading evidence for clinical guidelines

Jenny Evans

Cochrane methods for live reviews and the evidence pipeline

Toby Lasserson

London reading material

IOP measurement - Goldmann Applanation Tonometry

IOP measurement - Calibration of Goldmann Tonometer

FC I - Suggested Questions for Your Glaucoma Patient

FC II - Diagnostic Gonioscopy in Open Angle Glaucoma

FC III - Initial Visual Field Test Interpretation

FC IV - Diagnostic strategy when initial visual field is abnormal

FC V - Assessment and Follow-Up Intervals

FC VI - Treatment Options

FC VII - Management of Chronic Angle Closure

FC VIII - Management of Acute Primary Angle Closure Attack

FC IX - Considerations on Target IOP

FC X - Setting the Target IOP

FC XI - Adjustment of Target IOP

FC XII - Considerations on First Choice Medical Treatment

FC XIII - Medical Management - Choosing Therapy

FC XIV - Therapeutical Algorithm in Glaucoma Topical Therapy

Fig.I.4.1 - Functional loss over time guides Individualised treatment

Fig.I.7.1 - Landmark RCTs for glaucoma and year of first published results

Fig.II.1.1 - Technique of Goldmann Applanation Tonometry

Fig.II.1.2 - Technique of Goldmann Applanation Tonometry

Fig.II.1.3 - Corneal Wedge

Fig.II.1.4 - Direct and Indirect Gonioscopy

Fig.II.1.5 - Double Hump

Fig.II.1.6 - Dynamic Indentation Gonioscopy

Fig.II.1.7 - The Spaeth Grading System of Gonioscopy Finding

Fig.II.1.8 - The Van Herick Test

Fig.II.1.9 - The ISNT Rule

Fig.II.1.10 - Progression of Glaucomatous Damage at the Optic Disc

Fig.II.1.11 - Optic Disc Haemorrhage.

Fig.II.1.12 - ONH with Parapapillary Atrophy

Fig.II.1.13 - Optic Disc Size Assessed at the Slit Lamp with Handheld High Power Convex Lens

Fig.II.1.14 - Optic Nerve Heads

Fig.II.3.1 - The Whom-To-Treat Graph

Fig.II.3.2 - Diagrammatic Evaluation of Target IOP

Fig.II.3.3 - The Pre - Post IOP Graph.

Fig.II.3.4 - IOP Lowering Molecules and Year of First Clinical Use

EGS Education Continuum

Glaucoma curriculum

Evaluation scale

1st EGS Refresher Glaucoma Course for EBO Exam 2021 - Part 1

1st EGS Refresher Glaucoma Course for EBO Exam 2021 - Part 2

Instructional Course 1 - Algorythm for medical treatment of glaucoma

Luca Rossetti (Italy)

Instructional Course 2 - Can AI help better management of glaucoma? (Talk 1)

Hans G. Lemij (Netherlands)

Instructional Course 2 - Can AI help better management of glaucoma? (Talk 2)

Leopold Schmetterer (Singapore)

Instructional Course 3 - Clinical trials reviews (Talk 1)

Hari Jayaram (United Kingdom)

Instructional Course 3 - Clinical trials reviews (Talk 2)

Panayiota Founti (United Kingdom)

Instructional Course 4 - Congenital glaucoma (Talk 1)

Esther M. Hoffmann (Germany)

Instructional Course 4 - Congenital glaucoma (Talk 2)

Franz Grehn (Germany)

Instructional Course 5 - Glaucoma medication (Talk 1)

Gauti Johannesson (Iceland)

Instructional Course 5 - Glaucoma medication (Talk 2)

Gerhard Garhöfer (Austria)

Instructional Course 6 - MIGS and their complications (Talk 1)

James F. Kirwan (United Kingdom)

Instructional Course 6 - MIGS and their complications (Talk 2)

Jose Maria Martinez De La Casa (Spain)

Instructional Course 7 - Neuroprotection in Glaucoma - Update

Maria Francesca Cordeiro (United Kingdom)

Instructional Course 7 - What about nutritional remedies and glaucoma?

Miriam Kolko (Denmark)

Instructional Course 8 - SLT who, when, how and whom to? (Talk 1)

Stefano Gandolfi (Italy)

Instructional Course 8 - SLT who, when, how and whom to? (Talk 2)

Gus Gazzard (United Kingdom)

Instructional Course 9 - Sparing the ocular surface

Christophe Baudouin (France)

Instructional Course 10 - The new EGS guidelines (Talk 1)

Augusto Azuara-Blanco (United Kingdom)

Instructional Course 10 - The new EGS guidelines (Talk 2)

Carlo Enrico Traverso (Italy)

Instructional Course 11 - OCT Angiography in Glaucoma Diagnosis

Eduardo Maria Normando (United Kingdom)

Instructional Course 11 - Wide field OCTA in glaucoma

Leopold Schmetterer (Singapore)

Instructional Course 12 - What is new in pathophysiology of exfoliation?

Gábor Holló (Hungary)

Instructional Course 12 - What is new in the management of Exfoliative Glaucoma (XFG)?

Anastasios G. P. Konstas (Greece)

Instructional Course 13 - Virtual clinics in Covid Times

Anja Tuulonen (Finland)

Instructional Course 13 - How to manage increasing numbers of Glaucoma Patients; shared care and virtual clinics

Hans G. Lemij (Netherlands)

Instructional Course 14 - The worst surgical case

Keith Barton (United Kingdom)

Instructional Course 16 - APGS instruction course: Differences in Asia Pacific Laser Treatment

Seng Kheong Fang (Malaysia)

Instructional Course 16 - Differences in Surgical Outcomes of Glaucoma in Asians

Prin Rojanapongpun (Thailand)

Instructional Course 17 - Real-world outcomes in the big data era

Anthony Khawaja (United Kingdom)

Instructional Course 19 - Where are we with MIGS?

Leon Au (United Kingdom)

Instructional Course 20 - Visual Field in Glaucoma

Ananth C. Viswanathan (United Kingdom)

Instructional Course 21 - Safe cataract surgery in glaucomatous eyes

Carlo Enrico Traverso (Italy)

Instructional Course 22 - Trabeculectomy

Stefano Gandolfi (Italy)

Inaugural Next Generation Partnership Special Interest Group meeting

David Garway-Heath, Esther Hoffman, Gauti Johannesson, Francesco Oddone, Anja Tuulonen

Welcome and meeting objectives

David Garway-Heath

Definition of Glaucoma

Harry Quigley

Care quality and effectiveness from the societal perspective

Richard Wormald

Clinical markers of care quality and effectiveness

David Garway-Heath

Outcomes Research - goals and ambition

Norbert Pfeiffer

What matters to patients?

Carol Bronze

What patient-focussed outcomes can we measure?

Pradeep Ramulu

Measuring care effectiveness: the Finnish experience

Anja Tuulonen

The IRIS registry: the American approach

Joshua Stein

Big data approaches to collecting outcomes

David Crabb

Plenary session 1 - The moving eye: dynamic biomechanics of the optic disc/peripapillary tissues

Michael Girard

Plenary session 1 - The architecture of the back of the eye: static biomechanics of the ONH

Claude Burgoyne

Plenary session 1 - Retinal changes in glaucoma. 11 layer segmentation of OCT images

Leopold Schmetterer

Plenary session 1 - Can we image RGCs to understand and quantify the rate of glaucomatous loss?

Balwantray Chauhan

Plenary session 2 - What does angio-OCT tell us about glaucoma pathophysiology?

Felipe Medeiros

Plenary session 2 - Investigating the retinal vasomotricity with adaptive optics ophthalmoscopy

Michel Pâques

Plenary session 2 - Can structural CNS explorations help us to understand glaucoma?

Leonard Levin

Plenary session 2 - In vivo imaging of metabolic and functional brain changes in glaucoma

Kevin Chan

Plenary session 2 - Steady-state VEP for ON/OFF pathway RGCs in glaucoma

Jeffrey Goldberg

Plenary session 2: Imaging the vascular and neuronal compartments - Round table

Plenary session 3 - Recent advances in analysing the human genome

Emmanouil Dermitzakis

Plenary session 3 - Genetic risk factors

Janey Wiggs

Plenary session 3 - Mitochondrial dysfunction

Jonathan Crowston

Plenary session 3 - “Glaucomics”: new biomarkers for screening?

Pirro Hysi

Plenary session 3: Genes and gene expression - Round table

Plenary session 4 - Do vascular susceptibility factors define a phenotypic difference?

Jeffrey Liebmann

Plenary session 4 - Does the heterogeneity of genetic susceptibility factors lead to phenotypic differences?

Anthony Khawaja

Plenary session 4 - Optic disk appearance and genetic background

Ananth Viswanathan

Plenary session 4: A dive into precision medicine - Round table

Plenary session 5 - What is Artificial Intelligence and what are potential applications in medicine?

Marco Lorenzi

Plenary session 5 - What do we need to do to pave the way for Artificial Intelligence?

Konstantinos Balaskas

Plenary session 5 - Building an algorithm for glaucoma screening

Ryan Amelon

Plenary session 5: Artificial intelligence: the next frontier - Round table

Sessions 6 - The power of Artificial Intelligence to transform clinical trials

Vincent Diebolt

Sessions 6 - Artificial Intelligence: pitfalls, ethical aspects, confidentiality, patients perspective

David Gruson

Session 6 - Planning ahead: how to keep up with advancing Artificial Intelligence

Peter Thomas

Session 6 - Career and skill planning for glaucoma specialists in the era of Artificial Intelligence

Joshua Stein

Session 6 - Artificial intelligence: expectations and limits - Round table

Why should we avoid the use of prostaglandins unilaterally?

João Breda

Why should we provide good enough glaucoma care?

Gauti Johannesson

What is the role of cataract surgery in glaucoma management?

Luis Abegão Pinto

Why is individualized treatment so important?

Miriam Kolko

How to diagnose and treat aqueous misdirection?

Verena Prokosch

Why genomics-enabled precision glaucoma care is coming sooner than you may think?

Anthony Khawaja

Landmark studies and their influence on daily glaucoma management

Frances Meier-Gibbons

Is home glaucoma monitoring feasible and do we need it?

Andrew Tatham

What do we need to do to pave the way for AI in glaucoma care?

Marta Pazos

What is the role of OCT imaging in diagnosing glaucoma?

Francesco Oddone